Cellectar Biosciences Chief Scientific Officer Receives International Recognition for Pioneering Research
20 November 2015 - 2:30PM
Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused
biotechnology company, today announces that its chief scientific
officer and company founder, Jamey Weichert, Ph.D., received the
Harry Fisher award for excellence in contrast media research during
the 2015 Contrast Media Research Congress (CMR) held in Berlin,
Germany November 8-11, 2015.
"Jamey's ground-breaking contrast media imaging research is
renowned throughout the industry. We are extremely happy for Jamey
and proud to have this award-winning scientist as part of our
management and research team," said Jim Caruso, president and CEO
of Cellectar Biosciences. "Cellectar has leveraged Jamey's
extensive diagnostic and optical imaging PDC Delivery Platform
research to accelerate the advancement of our therapeutic product
portfolio including our recently introduced CTX Cytotoxic Conjugate
Program.
Dr. Weichert's award recognizes his many years of innovation and
leadership in the field, and coincides with his Berlin presentation
on November 8 titled, "Merging Molecular Imaging and Therapy:
Exploiting a Multi-modal Phospholipid Ether Delivery Platform for
Broad Spectrum Cancer Imaging and Therapy." The talk outlined the
early development, preclinical assessment and human clinical
studies of the company's PDC delivery platform, including
diagnostic imaging PDCs CLR 1502 and CLR 124, as well as its
lead radiotherapeutic PDC, CLR 131, currently in a Phase 1 study
for the treatment of relapsed or refractory multiple myeloma.
"The fact that we can use imaging to quantitatively guide cancer
therapies and possibly predict response is key in the development
of new cancer treatments. Unlike classical chemotherapy agents we
have the ability to monitor our therapy agents in four dimensions,
an unimaginable feat 10 years ago," said Dr. Weichert. "CMR is
a prominent international group of academic and industrial thought
leaders in the field of imaging and contrast agent development. To
receive the highest award given by this select group of colleagues
in my field is both extremely meaningful and humbling."
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC platform is based on the company's proprietary
phospholipid ether analogs. These novel small-molecules have
demonstrated highly selective uptake and retention in a broad range
of cancers. Cellectar's PDC pipeline includes product candidates
for cancer therapy and cancer diagnostic imaging. The company's
lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic
radioisotope, as its payload. CLR 131 is currently being evaluated
under an orphan drug designated Phase 1 study in patients with
relapsed or refractory multiple myeloma. The company is also
developing PDCs for targeted delivery of chemotherapeutics such as
paclitaxel (CLR 1603-PTX), a preclinical stage product candidate,
and plans to expand its PDC chemotherapeutic pipeline through both
in-house and collaborative R&D efforts. For additional
information please visit www.cellectarbiosciences.com.
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form
10-K/A for the year ended December 31, 2014. These
forward-looking statements are made only as of the date hereof, and
we disclaim any obligation to update any such forward-looking
statements.
CONTACT: INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024